Table 4.

Estimated indirect costs incurred per employed patient during the 8-week trial period

Time period	Indirect cost per period, $
	Vehicle	0.75% Ruxolitinib cream	1.5% Ruxolitinib cream
Weeks 0–2	569	525	497
Weeks 2–4	507	281	278
Weeks 4–6	460	263	230
Weeks 6–8	472	243	236